Document Type : Original Article
Authors
- Hamid Sanei 1
- Kiyan Heshmat-Ghahdarijani, MD 2
- Ali Asadi 3
- Mohammad Kermani-Alghoraishi, MD 4
- Ali Safaei 5
- masoumeh Sadeghi 6
1 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
3 Cardiologist, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute; Isfahan University of Medical Sciences, Isfahan, Iran
4 Associate Professor, Interventional Cardiologist, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5 Researcher, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute; Isfahan University of Medical Sciences, Isfahan, Iran
6 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
Background: The use of allopurinol has shown promising outcomes in favor of reducing oxidative processes responsible for atherogenic-related cardiovascular events. The current study aims to assess the effects of high-dose allopurinol on the post-revascularization coronary blood flow and inflammatory biomarkers in patients with non-ST segment elevated myocardial infarction (NSTEMI).Methods: Eighty NSTEMI patients were randomly divided into two groups, including the intervention group (n=40) medicated with a high loading dose of 600 mg allopurinol before the coronary angiography, while the control group (n=40) were treated with placebo. The highly sensitive C-reactive protein (hs-CRP) was measured at baseline and within 24 hours after the cardiac interventions and compared between the case and control groups. Post percutaneous coronary intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) flow grading was also evaluated as a revascularization endpoint.Results: The two groups of the study were similar in terms of demographic, clinical, laboratory and angiographic characteristics (P-value>0.050). The assessed TIMI flow was similar between the cases and the controls both prior to (P-value=0.141) and after (P-value=0.395) the coronary angioplasty. The hs-CRP (P-value=0.016) was significantly higher in the control group. Post-angiographic assessment of hs-CRP revealed insignificant difference between the groups (P-value=0.104).Conclusion: In conclusion, premedication with high dose allopurinol in NSTEMI patients did not affect inflammatory biomarker as well as revascularization endpoint.
Keywords
)